X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the Phase II grant, Plex intends to advance its lead anti-cataract drug candidate, CAP4196 through preclinical and IND enabling studies to gain clearance from the FDA to initiate its first-in-human clinical trials for the non-surgical treatment of cataracts.
Lead Product(s): CAP4196
Therapeutic Area: Ophthalmology Product Name: CAP4196
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding July 08, 2020
Details:
The funds will be used to optimize and develop the already identified lead candidate for advancement into in-vivo proof of concept translational studies.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
